Justice Department, Drug Enforcement Administration Briefing 2026-08-11
Estimated reading time: 5 minutes
1. Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
Sub: Justice Department, Drug Enforcement Administration
Content: The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2. Adjudication of Civil Penalties Against International Marriage Brokers
Sub: Justice Department
Content: This interim final rule ("IFR") amends Department of Justice ("Department") regulations to specify the procedures for adjudicating alleged violations of the International Marriage Broker Regulation Act of 2005 ("IMBRA") by international marriage brokers ("IMBs") doing business in the United States that fail to provide required information to persons recruited for matchmaking services or that improperly disclose prohibited information. This IFR is necessary to deter fraudulent marriages and the exploitation of immigrants recruited by IMBs.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
